Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00694707 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 732
- Enrollment target
- 20
- Study locations
NCT00694707: Completed Phase 2 study of Schizophrenia, sponsored by Forest Laboratories.
NCT00694707 is a Phase 2 study of Schizophrenia that has completed, run by Forest Laboratories. The registered enrollment target is 732 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (237% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00694707, a Phase 2 study of Schizophrenia, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 732 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.
Primary Outcome
The Positive and Negative Syndrome Scale (PANSS) is a 30-item rating scale that assesses the positive and negative symptoms of individuals with schizophrenia. Responses to the 30 items are based on a structured clinical interview with the patient and on supporting clinical information obtained from family, hospital staff, or other reliable informants. Of the 30 psychiatric parameters measured by the scale, 7 assess positive symptoms (eg, delusions, grandiosity); 7 assess negative symptoms (eg, b
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG Cariprazine
Study Locations (20)
California
- Forest Investigative Site - Costa Mesa
- Forest Investigative Site - Long Beach
- Forest Investigative Site - Oceanside
- Forest Investigative Site - Paramount
- Forest Investigative Site - Riverside
Texas
- Forest Investigative Site - Houston
- Forest Investigative Site - Houston
- Forest Investigative Site - Irving
Florida
- Forest Investigative Site - Bradenton
- Forest Investigative Site - Kissimmee
District of Columbia
- Forest Investigative Site - Washington D.C.
Louisiana
- Forest Investigative Site - Lake Charles
Maryland
- Forest Investigative Site - Baltimore
Mississippi
- Forest Investigative Site - Flowood
Missouri
- Forest Investigative Site - Bridgeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 2008-06-30 |
| Est. Completion | 2009-08-31 |
| Phase | Phase 2 |
What the finished NCT00694707 record still lists
NCT00694707 is an interventional study that assigns participants to a tested intervention. The registered 732 participants enrollment target is mid-sized for trials with a published cap, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (237% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00694707 names 20 study sites across 13 states, led by California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT00694707 about?
NCT00694707 is a clinical study titled "Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia". This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.
What is the current status of trial NCT00694707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 732 participants. The study started on 2008-06-30. Estimated completion is 2009-08-31.
What conditions does trial NCT00694707 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00694707?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), Cariprazine (DRUG).
Who is sponsoring clinical trial NCT00694707?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00694707 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00694707's enrollment target sits among peer trials
732 18th of 315 higher than 298 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI